- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00942643
Endothelial Damage and Atherosclerosis in Obstructive Sleep Apnea
Endothelial Damage and Atherosclerosis in Obstructive Sleep Apnea: the Role of Advanced Glycation End-products
The investigators hypothesize that obstructive sleep apnea (OSA) may lead to increased formation/accumulation of advanced glycation ends (AGEs), and that the increase in AGEs is contributed in part by increased insulin resistance. The investigators further hypothesize that AGEs contribute to vascular endothelial damage and ultimately atherosclerosis in OSA.
The objectives of this study are:
- To explore the relationship between insulin resistance and AGEs in OSA
- To study the relationship between AGE and vascular endothelial dysfunction in OSA
- To study the relationship between AGE and early atherosclerosis in OSA
Study Overview
Status
Intervention / Treatment
Detailed Description
There is growing evidence to suggest that pathophysiology of OSA may lead to atherosclerosis, independent of confounding variables which are often present in these subjects with OSA. Many mechanisms have been reported to contribute to vasculopathy in OSA, but whether increased AGEs formation contribute significantly to the pathogenesis of cardiovascular morbidity in OSA remains to be determined.
Advanced glycation product is formed by non-enzymatic reaction of reducing sugars such as glucose with the amino groups of proteins, and subsequent glycoxidation. AGEs can form on long-lived extracellular proteins as well as short-lived molecules, cytoplasmic proteins and nuclear acids. AGEs cause a number of adverse cellular events and they have been demonstrated in fatty streaks and atherosclerotic plaques. The formation and tissue accumulation of AGE is shown to be enhanced by hyperglycemia and/or increased oxidative stress. There is increasing evidence to support this as an important mechanism of vascular and other end organ damage in diabetes and some other diseases. In OSA, there is evidence to support an increased insulin resistance and excessive oxidative stress, both of which may predispose to AGE formation. We have preliminary data to suggest increased levels of circulating AGE in non-diabetic OSA subjects. Since insulin resistance with elevated blood glucose levels, albeit not up to diabetic thresholds, may partially contribute to increase in AGE.
Many potential mechanisms of atherosclerosis have been reported, but direct evidence for atherosclerosis is still lacking. Subjects with OSA also have comorbidities which may give rise to atherosclerosis. With the advancement of non-invasive techniques for detection of vascular endothelial damage and early atherosclerosis, it is possible to detect early vascular abnormalities in otherwise healthy OSA subjects. This hypothesis underlies our objectives to explore the relationship between AGE and the markers of endothelial dysfunction and early atherosclerosis. Some of these early changes, especially at endothelial level, may be reversible if the insult of OSA is removed. Thus a longitudinal comparison of OSA-treated and OSA-untreated subjects on such changes would further help to clarify the issue.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Pokfulam, Hong Kong
- Queen Mary Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age 18-65 years old
- AHI >= 15
- BMI < 35
Exclusion Criteria:
- Known cardiovascular disease, including hypertension
- Diabetes
- Acute or unstable chronic disease
- Renal failure
- Major organ system failure, including liver, renal, cardiac and respiratory failure
- Taking long-term medications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: no treatment
being observed at 4 weeks and 12 weeks
|
|
|
Active Comparator: CPAP treatment
a machine delivers positive airway pressure into the upper airway via nasal mask
|
a machine delivers positive airway pressure into the upper airway via a nasal mask
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
AGEs levels
Time Frame: 4 weeks and 12 weeks
|
4 weeks and 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
endothelial function as assessed by reactive hyperemia-induced peripheral arterial tone response
Time Frame: 4 weeks and 12 weeks
|
4 weeks and 12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mary SM Ip, MD, Queen Mary Hospital, The University of Hong Kong
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Nervous System Diseases
- Respiratory Tract Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Respiration Disorders
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Signs and Symptoms, Respiratory
- Hyperinsulinism
- Sleep Apnea Syndromes
- Sleep Apnea, Obstructive
- Apnea
- Insulin Resistance
- Atherosclerosis
Other Study ID Numbers
- HKCTR-772
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.